Does continued antithrombotic therapy increase clinically significant hemorrhagic complications in patients undergoing TRUS-guided prostate biopsy?
Continuing antithrombotic therapy during TRUS-guided prostate biopsy appears feasible and safe, particularly for patients at high thromboembolic risk.
TRUS-guided prostate biopsy under sacral anesthesia appeared feasible without discontinuation of antithrombotic therapy and was not associated with a clear excess of clinically significant hemorrhagic complications. In selected patients, particularly those at high thromboembolic risk, continuing antithrombotic therapy may be a reasonable option, although a modest increase in bleeding risk cannot be definitively excluded.
Akagi et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: